BioFactura's BFI-751, a Biosimilar Ustekinumab, Demonstrates Pharmacokinetic (PK) Bioequivalence to Stelara® in Phase 1 Study
Frederick, Maryland (PRWEB) October 14, 2022 -- BioFactura Inc. has announced today the completion of the pivotal pharmacokinetic comparability clinical trial
Source: prweb.com